Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 444

1.

Recent trends in sexual behaviours among MSM followed since primary HIV-1 infection.

Champenois K, Seng R, Persoz A, Essat A, Gaud C, Laureillard D, Robineau O, Duvivier C, Yazdanpanah Y, Goujard C, Meyer L; ANRS PRIMO cohort study group.

AIDS. 2018 Jun 20. doi: 10.1097/QAD.0000000000001916. [Epub ahead of print]

PMID:
29927787
2.

Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.

Lê MP, Chaix ML, Chevret S, Bertrand J, Raffi F, Gallien S, El Abbassi EMB, Katlama C, Delobel P, Yazdanpanah Y, Saillard J, Molina JM, Peytavin G; ANRS 165 DARULIGHT Study Group .

J Antimicrob Chemother. 2018 Jun 13. doi: 10.1093/jac/dky193. [Epub ahead of print]

PMID:
29905808
3.

Risk of diabetes in HIV-infected patients is associated with cirrhosis but not with chronic HCV coinfection in a French nationwide HIV cohort.

Provoost A, Dramé M, Cotte L, Cuzin L, Garraffo R, Rey D, Raffi F, Poizot-Martin I, Pugliese P, Bani-Sadr F; Dat'AIDS study group.

Aliment Pharmacol Ther. 2018 Jun 14. doi: 10.1111/apt.14812. [Epub ahead of print]

PMID:
29901821
4.

Costs Associated with Hospitalisation in Hiv-Positive Patients in France.

de Léotoing L, Yazdanpanah Y, Finkielsztejn L, Chaize G, Vainchtock A, Nachbaur G, Aubin C, Bonnet F.

AIDS. 2018 Jun 11. doi: 10.1097/QAD.0000000000001907. [Epub ahead of print]

PMID:
29894390
5.

Factors associated with deaths from suicide in a French nationwide HIV-infected cohort.

Hentzien M, Cabie A, Pugliese P, Billaud É, Poizot-Martin I, Duvivier C, Valantin MA, Kaladjian A, Dramé M, Bani-Sadr F; Dat'AIDS Study Group.

HIV Med. 2018 Jun 1. doi: 10.1111/hiv.12633. [Epub ahead of print]

PMID:
29856132
6.

Plague: Bridging gaps towards better disease control.

D'Ortenzio E, Lemaître N, Brouat C, Loubet P, Sebbane F, Rajerison M, Baril L, Yazdanpanah Y.

Med Mal Infect. 2018 May 14. pii: S0399-077X(18)30133-1. doi: 10.1016/j.medmal.2018.04.393. [Epub ahead of print] Review.

PMID:
29773334
7.

Voluntary Community Human Immunodeficiency Virus Testing, Linkage, and Retention in Care Interventions in Kenya: Modeling the Clinical Impact and Cost-effectiveness.

Luong Nguyen LB, Yazdanpanah Y, Maman D, Wanjala S, Vandenbulcke A, Price J, Parker RA, Hennequin W, Mendiharat P, Freedberg KA.

Clin Infect Dis. 2018 May 8. doi: 10.1093/cid/ciy173. [Epub ahead of print]

PMID:
29746619
8.

Scale-up of HIV self-testing.

Jakobsen SF, Raben D, Sperle I, Lazarus JV, James C, Mendão L, de Wit J, Platteau T, von Lingen AI, Corbelli GM, Antoniadi C, Casabona J, West B, Rockstroh J, Delpech V; HIV in Europe Steering Committee.

HIV Med. 2018 May 8. doi: 10.1111/hiv.12618. [Epub ahead of print] No abstract available.

PMID:
29737617
9.

Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.

Cousien A, Tran VC, Deuffic-Burban S, Jauffret-Roustide M, Mabileau G, Dhersin JS, Yazdanpanah Y.

J Viral Hepat. 2018 Apr 16. doi: 10.1111/jvh.12919. [Epub ahead of print]

PMID:
29660211
10.

[The plague: An overview and hot topics].

Galy A, Loubet P, Peiffer-Smadja N, Yazdanpanah Y.

Rev Med Interne. 2018 Apr 5. pii: S0248-8663(18)30117-6. doi: 10.1016/j.revmed.2018.03.019. [Epub ahead of print] French.

PMID:
29628173
11.

Intervention Packages to Reduce the Impact of HIV and HCV Infections Among People Who Inject Drugs in Eastern Europe and Central Asia: A Modeling and Cost-effectiveness Study.

Mabileau G, Scutelniciuc O, Tsereteli M, Konorazov I, Yelizaryeva A, Popovici S, Saifuddin K, Losina E, Manova M, Saldanha V, Malkin JE, Yazdanpanah Y.

Open Forum Infect Dis. 2018 Feb 17;5(3):ofy040. doi: 10.1093/ofid/ofy040. eCollection 2018 Mar.

12.

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.

Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Xu X, Rodgers A, Lupinacci L, Kumar S, Sklar P, Nguyen BY, Hanna GJ, Hwang C; DRIVE-FORWARD Study Group.

Lancet HIV. 2018 May;5(5):e211-e220. doi: 10.1016/S2352-3018(18)30021-3. Epub 2018 Mar 25.

PMID:
29592840
13.

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM).

Meynard JL, Moinot L, Landman R, Morand-Joubert L, Besseghir A, Kolta S, Spire B, Todesco E, Bouchaud O, Fagard C, Chene G, Girard PM; ANRS 140 DREAM Study Group .

J Antimicrob Chemother. 2018 Jun 1;73(6):1672-1676. doi: 10.1093/jac/dky055.

PMID:
29584910
14.

High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort.

Charpentier C, Peytavin G, Lê MP, Joly V, Cabras O, Perrier M, Le Gac S, Phung B, Yazdanpanah Y, Descamps D, Landman R.

J Antimicrob Chemother. 2018 Jun 1;73(6):1665-1671. doi: 10.1093/jac/dky062.

PMID:
29528412
15.

Pneumocystis Cytochrome b Mutants Associated With Atovaquone Prophylaxis Failure as the Cause of Pneumocystis Infection Outbreak Among Heart Transplant Recipients.

Argy N, Le Gal S, Coppée R, Song Z, Vindrios W, Massias L, Kao WC, Hunte C, Yazdanpanah Y, Lucet JC, Houzé S, Clain J, Nevez G.

Clin Infect Dis. 2018 Mar 3. doi: 10.1093/cid/ciy154. [Epub ahead of print]

PMID:
29514207
16.

Hepatitis C: The beginning of the end-key elements for successful European and national strategies to eliminate HCV in Europe.

Papatheodoridis GV, Hatzakis A, Cholongitas E, Baptista-Leite R, Baskozos I, Chhatwal J, Colombo M, Cortez-Pinto H, Craxi A, Goldberg D, Gore C, Kautz A, Lazarus JV, Mendão L, Peck-Radosavljevic M, Razavi H, Schatz E, Tözün N, van Damme P, Wedemeyer H, Yazdanpanah Y, Zuure F, Manns MP.

J Viral Hepat. 2018 Mar;25 Suppl 1:6-17. doi: 10.1111/jvh.12875. Review.

PMID:
29508946
17.

Safety and efficacy of exposure to bedaquiline-delamanid in multidrug-resistant tuberculosis: a case series from France and Latvia.

Guglielmetti L, Barkane L, Le Dû D, Marigot-Outtandy D, Robert J, Veziris N, Yazdanpanah Y, Kuksa L, Caumes E, Fréchet-Jachym M.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702550. doi: 10.1183/13993003.02550-2017. Print 2018 Mar. No abstract available.

PMID:
29419439
18.

Cost-effectiveness of vaccination against cytomegalovirus (CMV) in adolescent girls to prevent infections in pregnant women living in France.

N'Diaye DS, Launay O, Picone O, Tsatsaris V, Azria E, Rozenberg F, Schwarzinger M, Yazdanpanah Y.

Vaccine. 2018 Feb 28;36(10):1285-1296. doi: 10.1016/j.vaccine.2018.01.042. Epub 2018 Feb 1.

PMID:
29397227
19.

Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine.

Néant N, Gattacceca F, Lê MP, Yazdanpanah Y, Dhiver C, Bregigeon S, Mokhtari S, Peytavin G, Tamalet C, Descamps D, Lacarelle B, Solas C.

Eur J Clin Pharmacol. 2018 Apr;74(4):473-481. doi: 10.1007/s00228-017-2405-1. Epub 2018 Jan 26.

PMID:
29374296
20.

Experiences and perspectives of implementing antimicrobial stewardship in five French hospitals: a qualitative study.

Perozziello A, Routelous C, Charani E, Truel A, Birgand G, Yazdanpanah Y, Lescure FX, Lucet JC; CEFECA Study Group.

Int J Antimicrob Agents. 2018 Jun;51(6):829-835. doi: 10.1016/j.ijantimicag.2018.01.002. Epub 2018 Jan 12.

PMID:
29339297

Supplemental Content

Loading ...
Support Center